bromfenac nonsteroidal antiinflammatory drug marketed us ophthalmic solution brand names prolensa prior formulation brand name xibrom since discontinued ista pharmaceuticals shortterm local use prolensa bromday oncedaily formulation bromfenac xibrom approved twicedaily administration european union brand name yellox bromfenac indicated treatment ocular inflammation pain cataract bromfenac indicated treatment postoperative ocular inflammation following cataract drug shown reduce macular edema thickness retina indicator inflammation improve visual acuity bromfenac contraindicated people adverse reactions nsaids asthma bromfenac eye drops generally well tolerated comparatively common side effects clinical studies included abnormal sensations eye people treated bromfenac mild moderate erosion cornea eye pruritus eye pain redness serious side effects corneal perforation reported studies postmarketing less one patient systematic interaction studies performed known cases interactions antibiotic eye blood plasma levels remain low bromfenac therapy interactions drugs taken mouth unlikely nsaid bromfenac works inhibiting prostaglandin synthesis blocking cyclooxygenase cox enzymes preferably acts low affinity bromfenac well absorbed cornea reaches highest concentrations aqueous humour minutes biological halflife hours high drug levels maintained least hours mainly concentrated aqueous humour conjunctiva much less lens vitreous concentrations blood plasma low measured quantitatively substance bound plasma proteins enzyme mainly responsible metabolization bromfenac metabolites include lactam several conjugated compounds excreted via urine via compared amfenac halogenation bromfenacs chemical structure bromine atom increases penetration ocular tissues increases potency cox enzyme along indomethacin diclofenac others bromfenac belongs acetic acid group nsaids used form bromfenac sodium cas number soluble water methanol aqueous bases insoluble chloroform aqueous acids melts ophthalmic use bromfenac prescribed times across eye drop available since starting japan sold first fda approved use united states marketed xibrom october bromday received fda approval new oncedaily formulationcitation needed recently prolensa also approved bromfenac eye drops marketed european union since available worldwide markets agreements bausch cromapharma companiescitation needed bromfenac formerly marketed united states wyethayerst oral formulation called duract shortterm relief pain less days time brought market july withdrawn june following numerous reports hepatotoxicity patients taken medication longer recommended httpsenwikipediaorgwikibromfenac